IM Cannabis Secures $250K Convertible Note Financing from…

Event summary

IM Cannabis Corp. closed a $250,000 convertible note financing with an institutional investor on August 7, 2026.
The note bears an 8% annual interest rate, increasing to 14% in case of default, and is convertible into common shares.
Conversion price is set at the lower of $0.122 per share or 90% of the lowest daily volume-weighted average price over 20 trading days preceding conversion, with a floor of $0.02436.
The company issued warrants to purchase up to 2,052,545 common shares at an exercise price of C$0.17 per share, exercisable immediately and expiring on August 7, 2031.

The big picture

This financing comes as IM Cannabis continues to navigate a challenging regulatory environment in both Israel and Germany. The convertible note structure suggests a strategic move to extend its runway while potentially diluting existing shareholders. The deal size, though modest, indicates cautious optimism from institutional investors amid broader market uncertainties in the medical cannabis sector.

What we're watching

Liquidity Strategy: How IM Cannabis will deploy the $250,000 proceeds for general corporate purposes and whether it can secure additional funding to support its operations.
Shareholder Dynamics: The impact of potential share issuance upon conversion of the note and exercise of warrants on the company's ownership structure and market capitalization.
Regulatory Compliance: The timeline for filing and securing effectiveness of the resale registration statement with the SEC, which is critical for the liquidity of the securities issued.